About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients

A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients

NCT01298518·3 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Pfizer

Age

18–60

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Male and/or female subjects between the ages of 18 and 60 years;
Body Mass Index (BMI) of \>25.0 kg/m2 and \<40 kg/m2;
Subjects must have a historical diagnosis of T2DM in accordance with the ADA guidelines;
Subjects who have been on well-tolerated and stable doses of metformin

You may not be if

Recent evidence (6 months prior to screening) or history of unstable major organ disease;
Diagnosis of Type 1 diabetes mellitus;
Current medical history of myocardial infarction, unstable angina, or history of stroke (including TIA) within 6 months prior to Screening;
Treatment with thiazolidinediones (TZDs), or subcutaneously administered antidiabetic agents;

The record

StatusCompleted

PhasePhase 1

Taking part48

StartedFeb 2011

UpdatedNov 6, 2012

Conditions

Type 2 Diabetes Patients

Where3

Pfizer Investigational Site
Chula Vista, California, United States
Pfizer Investigational Site
DeLand, Florida, United States
Pfizer Investigational Site
Miami Gardens, Florida, United States